Celltrion, Inc. (068270.KS) is in Healthcare, Biotechnology, based in South Korea, listed on KSE. Market cap 40.95T KRW. 52-week range 158,500.00 to 239,047.62 KRW. Data as of 2026-10-09.
Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of development, production, and sale of medicinal products. It offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin's lymphoma and chronic lymphocytic leukemia; Herzuma for metastatic breast and gastric cancer; Remsima SC and Yuflyma for rheumatoid arthritis and inflammatory bowel disease; Vegzelma for metastatic colorectal cancer and ...